European Commission Approves Update of Erbitux Metastatic Colorectal Cancer Labeling to Patients With RAS Wild-Type Tumors
The European Commission's approval is based on the CHMP positive opinion
Label update comes in response to new biomarker data obtained from the OPUS study
DARMSTADT, Germany, Dec. 23, 2013 -- (Healthcare Sales & Marketing Network) -- Merck Serono, t... Biopharmaceuticals, Oncology, RegulatoryMerck Serono, Erbitux, cetuximab, metastatic colorectal cancer, RAS tumor
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news
More News: Cancer | Cancer & Oncology | Colorectal Cancer | Erbitux | Marketing | Merck | Pharmaceuticals | Study